Literature DB >> 1188622

Intermittent claudication: its natural course.

A M Imparato, G E Kim, T Davidson, J G Crowley.   

Abstract

Of more than 600 patients seen for intermittent claudication by this group and not primarily considered for surgery, 104 had angiographic studies and are the basis for this report. The follow-up period varied from 6 months to 8 years, with a mean of 2.5 years. Classification by severity of claudication revealed 33 with less than one block, 36 with two blocks, and 35 with two or more blocks, foot, calf, or thigh claudication. Eighty-two remained stable or improved and 22 worsened. Of the 22 who worsened, 16 had only worsening of claudication (six of them requiring arterial reconstruction) and six progressed to gangrene and required amputations. Of the 82, 66 either had marked improvement of claudication or remained sufficiently stable not to require any operative intervention. Sixteen required arterial reconstruction for persistent, intolerable, or incapacitating claudication. Five of the six amputees were from the less than one half block claudication group. Angiographic studies were significant only in relation to the below-knee runoff in that three of 25 with less than one vessel runoff, two of 23 with one to two vessel runoff, and one of 56 with two to three vessel runoff came to amputation, regardless of the pattern of more proximal arterial occlusions. The study suggests that intermittent claudication is relatively benign, with only 5.8 percent coming to amputation in a 2.5 year mean follow-up. Prognosis is determined by the severity of below-knee arterial involvement and apparent inability to compensate for ischemia via the collateral circulation since only 12.5 percent of those with the most pronounced involvement came to amputation.

Entities:  

Mesh:

Year:  1975        PMID: 1188622

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  23 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Peripheral Arterial Disease.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

Review 3.  Current strategies in the diagnosis and management of lower extremity peripheral vascular disease.

Authors:  T J Wilt
Journal:  J Gen Intern Med       Date:  1992 Jan-Feb       Impact factor: 5.128

Review 4.  Peripheral arterial disease in diabetes: is there a role for genetics?

Authors:  Arabindra B Katwal; Ayotunde O Dokun
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

5.  Fate in intermittent claudication: outcome and risk factors.

Authors:  R Jelnes; O Gaardsting; K Hougaard Jensen; N Baekgaard; K H Tønnesen; T Schroeder
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

6.  Angiographic documentation of aortoiliac occlusion in Leriche's syndrome.

Authors:  Masateru Takigawa; Koichi Akutsu; Satoshi Kasai; Yuiichi Tamori; Tsuyoshi Yoshimuta; Masahiro Higashi; Satoshi Takeshita
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

7.  APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.

Authors:  Ellis S Sampram; Anders Gottsäter; Bengt Lindblad; Peter J Svensson
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

Review 8.  Evidence-based management of peripheral vascular disease.

Authors:  Nicolas W Shammas; Eric J Dippel
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 9.  Functional impairment in peripheral artery disease and how to improve it in 2013.

Authors:  Mary McGrae McDermott
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

10.  The perfusion index is a useful screening tool for peripheral artery disease.

Authors:  Hiroshi Okada; Muhei Tanaka; Takashi Yasuda; Tadaaki Kamitani; Hisahiro Norikae; Tetsuya Fujita; Takashi Nishi; Hirokazu Oyamada; Tetsuro Yamane; Michiaki Fukui
Journal:  Heart Vessels       Date:  2018-10-03       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.